Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases

• Published in: Urology (Ridgewood, N.J.) Vol. 63; no. 2; pp. 321 - 326
• Main Authors: Petrioli, Roberto, Rossi, Stefania, Caniggia, Mario, Pozzessere, Daniele, Messinese, Simona, Sabatino, Marianna, Marsili, Stefania, Correale, Pierpaolo, Salvestrini, Francesco, Manganelli, Antonio, Francini, Guido
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 01-02-2004; Elsevier Science
• Subjects: Adenocarcinoma - blood; Adenocarcinoma - drug therapy; Adenocarcinoma - mortality; Adenocarcinoma - secondary; Aged; Alkaline Phosphatase - blood; Androgen Antagonists - pharmacology; Androgen Antagonists - therapeutic use; Antineoplastic Agents, Hormonal - pharmacology; Antineoplastic Agents, Hormonal - therapeutic use; Biological and medical sciences; Biomarkers, Tumor - blood; Bone Neoplasms - blood; Bone Neoplasms - drug therapy; Bone Neoplasms - mortality; Bone Neoplasms - secondary; Calcium - urine; Collagen - blood; Collagen Type I; Creatinine - urine; Diseases of the osteoarticular system; Drug Resistance, Neoplasm; Follow-Up Studies; Gynecology. Andrology. Obstetrics; Humans; Italy - epidemiology; Karnofsky Performance Status; Life Tables; Male; Male genital diseases; Medical sciences; Middle Aged; Nephrology. Urinary tract diseases; Peptides - blood; Phosphopeptides - blood; Procollagen - blood; Proportional Hazards Models; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - mortality; Survival Analysis; Time Factors; Tumors; Tumors of striated muscle and skeleton; Tumors of the urinary system; Urinary tract. Prostate gland; Italy; Human; Hormone; Nephrology; Urinary system disease; Biochemical analysis; Prognosis; Prostate disease; Biochemical marker; Diseases of the osteoarticular system; Malignant tumor; Metastasis; Survival; Urology; Osteoarticular system; Resistance; Bone cancer; Bone; Male genital diseases; Prostate cancer
• ISSN: 0090-4295; 1527-9995
• DOI: 10.1016/j.urology.2003.09.044

To investigate the prognostic value of some conventional bone markers and a number of other factors in terms of the survival of patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.
The data of 141 patients were analyzed to verify the influence of the following factors on survival: bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, the urinary calcium/creatinine ratio, patient age, Karnofsky performance status, pathologic grade, duration of response to primary hormonal therapy, prostate-specific antigen, hemoglobin, lactate dehydrogenase, and extent of bone disease.
When all the variables were simultaneously analyzed using the multivariate proportional hazard model, only Karnofsky performance status (
P <0.005) and duration of response to primary hormonal therapy (
P <0.0001) remained statistically significant.
The results of this study suggest that bone-alkaline phosphatase, type I collagen propeptide, the carboxyterminal telopeptide of type I collagen, and the urinary calcium/creatinine ratio are not prognostic of survival in patients with hormone-resistant prostate cancer and bone metastases treated with chemotherapy.